相关实验视频

Updated: Sep 15, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

针对线粒体的抗生素对抗耐药TNBC

Miae Won^1,2, Changyu Yoon³, Jusung An³

¹College of Pharmacy, Dongduk Women's University, Seoul 02748, Korea.

ACS applied bio materials

|July 16, 2025

概括

一种针对线粒体的新型抗生素,化合物1 (CFX-TPP+),显示出克服三阴性乳腺癌 (TNBC) 耐药性的前景. 它增强了反应性氧物种 (ROS) 的产生,诱导癌细胞死亡,并可能提供没有复发的治疗方法.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

耐药性在癌症治疗中构成了重大挑战.
线粒体是通过活性氧物种 (ROS) 细胞存活和死亡的关键调节者.
向线粒体提供了一种提高癌症治疗效率和克服耐药性的策略.

研究的目的:

引入和评估一种针对线粒体的新型抗生素,化合物1 (CFX-TPP+),用于对抗耐药三阴性乳腺癌 (TNBC).
评估化合物1对TNBC细胞的稳定性和体外疗效.

主要方法:

合成和描述化合物1 (CFX-TPP+),一种针对线粒体的抗生素,具有胺基功能单元.
在血中评估化合物1的稳定性,与含有的类似物相比.
对抗耐药TNBC细胞的化合物1的细胞毒性评估 (MDA-MB-231).
分析ROS生成,线粒体氧化应激和下游的亡信号通路.

主要成果:

化合物1在血中表现出优越的稳定性,与其类对应物相比.
化合物1对耐药TNBC细胞表现出显著的细胞毒性.
用化合物1治疗导致ROS生成增强和线粒体氧化应激增加.
化合物1诱导了线粒体介导的亡,上调的BAX和参与线粒体生物发生的下调基因.

结论:

化合物1 (CFX-TPP+) 是一种稳定且有效的线粒体向药物耐药TNBC的药物.
这种方法显示出克服耐药性和在TNBC中实现疾病缓解的潜力.
准线粒体ROS为新型癌症疗法提供了一个有希望的战略.

关键词:

抗生素抗生素是一种抗生素.抗癌药物抗癌药物药物耐药性药物耐药性药物耐药性线粒体中的线粒体.线粒体细胞死亡线粒体细胞死亡反应性氧物种的反应性氧物种.三重阴性乳腺癌是什么?

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.